Shareholders are rewarding the kinds of companies they punished a year ago.
Success or failure on the stock markets this year depended almost entirely on whether a company’s devices could be used to treat coronavirus patients.
The good times continue to roll for big cap device makers, with two companies doubling their market value, and not a single share price fall.
Exact Sciences finds that where there’s muck there’s brass, but specialisation does not work as well for Abiomed.
Toothy grins all round at Align, but it is unclear how much longer it can keep up its scorching rate of sales growth.